Christoph Hoeller
Expertise in
2
conditions

Christoph Hoeller

Vienna, AT 
Expertise in
2
conditions
Vienna, AT 

Overview

Christoph Hoeller practices practicing medicine in Vienna, Austria.

Mr. Hoeller is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Melanoma, Basal Cell Skin Cancer, Oral Herpes, Neurocutaneous Melanosis, and Gamma Knife Radiosurgery.

He is actively involved in clinical research, co-authoring 110 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Vienna, Austria

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Three Arms Prospective, Randomized Phase II Study to Evaluate the Best Sequential Approach With Combo Immunotherapy (Ipilimumab/Nivolumab) and Combo Target Therapy (LGX818/MEK162) in Patients With Metastatic Melanoma and BRAF Mutation
A Three Arms Prospective, Randomized Phase II Study to Evaluate the Best Sequential Approach With Combo Immunotherapy (Ipilimumab/Nivolumab) and Combo Target Therapy (LGX818/MEK162) in Patients With Metastatic Melanoma and BRAF Mutation
Enrollment Status: Completed
Publish Date: June 07, 2024
Intervention Type: Drug
Study Drugs: LGX818, MEK162, Nivolumab, Ipilimumab
Study Phase: Phase 2
Multicenter Phase 2 Study to Identify of the Optimal Neo-Adjuvant Combination Scheme of Ipilimumab and Nivolumab (OpACIN-neo)
Multicenter Phase 2 Study to Identify of the Optimal Neo-Adjuvant Combination Scheme of Ipilimumab and Nivolumab (OpACIN-neo)
Enrollment Status: Unknown
Publish Date: November 15, 2023
Intervention Type: Procedure, Drug
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
View 1 Less Clinical Trial

110 Total Publications

Systemic Inflammation and Risk of Thromboembolism, Mortality, and Treatment Response in Patients With Cancer Receiving Immune Checkpoint Inhibitors.
Systemic Inflammation and Risk of Thromboembolism, Mortality, and Treatment Response in Patients With Cancer Receiving Immune Checkpoint Inhibitors.
Journal: European journal of clinical investigation
Published: March 27, 2026

Frequently Asked Questions about Christoph Hoeller

Is Christoph Hoeller a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Christoph Hoeller is classified as an Elite expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Christoph Hoeller participate in research or clinical trials?

Yes. Christoph Hoeller has published 110 articles and abstracts on conditions like Melanoma. You can view a list of Christoph Hoeller's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Hoeller's expertise for a condition
ConditionClose
    View All 14 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile